BeiGene (NASDAQ:BGNE) Trading Down 2.6%

BeiGene, Ltd. (NASDAQ:BGNE) dropped 2.6% on Friday . The company traded as low as $193.07 and last traded at $193.32. Approximately 20,332 shares traded hands during trading, a decline of 92% from the average daily volume of 244,450 shares. The stock had previously closed at $198.50.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BGNE shares. Bank of America lowered their target price on BeiGene from $180.00 to $152.50 and set a “neutral” rating on the stock in a research note on Tuesday, July 9th. TD Cowen upped their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Citigroup lifted their target price on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of BeiGene from $194.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, BeiGene has an average rating of “Moderate Buy” and a consensus price target of $239.81.

BeiGene Stock Down 3.4 %

The business has a 50-day moving average price of $167.72 and a 200-day moving average price of $160.51. The stock has a market cap of $18.58 billion, a PE ratio of -25.33 and a beta of 0.59. The company has a current ratio of 2.08, a quick ratio of 1.84 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.27) by $1.12. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The company had revenue of $929.20 million for the quarter, compared to analysts’ expectations of $810.34 million. During the same period in the previous year, the firm posted ($3.64) EPS. BeiGene’s revenue was up 56.1% compared to the same quarter last year. As a group, analysts forecast that BeiGene, Ltd. will post -7.76 earnings per share for the current year.

Insider Buying and Selling

In other BeiGene news, SVP Chan Henry Lee sold 834 shares of BeiGene stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total transaction of $133,915.38. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other BeiGene news, SVP Chan Henry Lee sold 834 shares of the firm’s stock in a transaction that occurred on Tuesday, July 30th. The shares were sold at an average price of $160.57, for a total value of $133,915.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Julia Aijun Wang sold 899 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $155.66, for a total value of $139,938.34. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,517 shares of company stock worth $1,190,004. 7.43% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in BeiGene during the first quarter worth about $50,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of BeiGene during the 4th quarter worth approximately $98,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of BeiGene during the 4th quarter valued at approximately $183,000. Acadian Asset Management LLC lifted its holdings in BeiGene by 204.1% in the first quarter. Acadian Asset Management LLC now owns 1,265 shares of the company’s stock valued at $197,000 after acquiring an additional 849 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in BeiGene in the first quarter worth approximately $209,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.